undamentalytics Newsletter
Sign in

Pacira Biosciences, Inc. balance sheet

At the end of fiscal 2025, Pacira Biosciences, Inc. had total assets of $1.26bn, total liabilities of $572m and shareholders' equity of $693m. It held $159m in cash against $372m of debt: net debt of $214m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents7264613133854365413378100586104153277159206
Receivables—12415222630323848539698106113124132
Inventory—211216296231414958659996104125153135
Total current assets—318361107214253243391478409652866498510745548615
Goodwill——0810243147556210010014516316302020
Total assets—671131121703263883916286898311,2752,0751,6811,5741,5541,2651,244
Accounts payable—433379815141310111516191518
Deferred revenue (current)—2131111100————————
Total current liabilities—16321412214015045566110825352114897310121122
Short-term debt—370120120119119———————2020—
Long-term debt—2219250103104109—————689522384372363
Total debt0252625120120119109276291306463690689522585372363
Total liabilities—11565461291551691723493684766551,345906704775572572
Shareholders' equity−23−48486641171218219279321355620730775870778693672
Net debt (negative = net cash)−7−1−2113107826473222158228363104585369309214157
Shares outstanding———33m34m36m37m37m41m41m42m44m45m46m46m46m41m40m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AMPH vs PCRXCORT vs PCRXPCRX vs TVTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Pacira Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pacira Biosciences, Inc.